Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001290708 | SCV001478845 | likely pathogenic | Hereditary thrombocytopenia and hematologic cancer predisposition syndrome | 2024-06-24 | reviewed by expert panel | curation | This late duplication which results in a frameshift is not expected to result in nonsense mediated mRNA decay, but will alter the transactivation domain/inhibitory domain/VWRPY motif and elongate the protein (PVS1_strong). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_Supporting). This variant is a frameshift variant that is downstream of c.98 (PM5_Supporting). It has been described in a patient with thrombocytopenia (personal communication with last author) and short telomeres (<1st percentile), but the variant could not be confirmed in the germline (PMID: 29463756). However, other C-terminal frameshift variants have been reported with some showing loss of transactivation ability and a dominant-negative effect (PMID: 14615365, 19808697, 25840971). In summary, the clinical significance of this variant is likely pathogenic. ACMG/AMP criteria applied, as specified by the ClinGen Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1_strong and PM2_supporting, PM5_supporting. |
Prevention |
RCV000680384 | SCV000807755 | likely pathogenic | not provided | 2018-07-12 | criteria provided, single submitter | clinical testing |